Inflammasome Therapeutics, a private, clinical-stage biotech company developing novel, first-in-class, dual inflammasome inhibitors for prevalent ophthalmic and neurodegenerative diseases, announced ...

Scientists have discovered why males get dental disease more frequently and with greater severity than females, pinpointing ...

"Enrolment concludes for Inflammasome’s K8 Phase II trial for GA" was originally created and published by Clinical Trials ...

Recurrent pericarditis is condition in which the pericardium, a double-layered sac that surrounds and protects the heart, is inflamed and ...

Analysis of human samples and mouse models shows inflammasome signaling drives bone resorption in males but not females, ...

Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...

Teaming up with the Healey & AMG Center, Inflammasome will advance its oral ALS drug kamuvudine-9, known as K9, into early clinical testing.

Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study. Parkinson ...